YouTube video by The Independent

YouTube video by New Order - Topic

Immunovant, argenx, Johnson & Johnson and UCB compete across an FcRn landscape where the indication and trial population matter. The comparison examines gMG, Graves disease, clinical setbacks, approved benchmarks and upcoming evidence. UCBJY trades OTC in the US.

argenx SE American Depositary Shares · $793.19 -14.57% · Healthcare

argenx (ARGX) will discontinue its Phase 3 UNITY study of subcutaneous efgartigimod in adults with moderate-to-severe Sjögren's disease.An Independent Data Monitoring Committee recommended stopping for futility following an interim analysis, concluding that the study could not meet its primary endpoint. That endpoint measured change from baseline in systemic disease activity at Week 48 using clinESSDAI, a clinical disease-activity index. Safety was consistent with efgartigimod's established profile, with no new safety signals identified.UNITY was randomized, double-blind and placebo-controlled, with an open-label extension. Patients were assigned equally to weekly efgartigimod SC or placebo. After study close and database lock, argenx plans an in-depth data analysis to understand the outcome and generate insights that may inform future Sjögren's research.

argenx (ARGX) announced that its Phase 2 study of FB102 in adults with celiac disease met its primary endpoint. FB102 showed a statistically significant effect versus placebo on the change from baseline in villus height-to-crypt depth ratio, a measure of intestinal tissue structure, at day 78 (p=0.0176) during a gluten challenge. Measures of intestinal immune-cell density, a composite tissue score and symptoms were consistent with the primary endpoint. The safety profile was consistent with prior studies, with no new safety signals identified.argenx plans to advance FB102 into Phase 3 development and share detailed Phase 2 results at an upcoming medical meeting. This was the first FB102 clinical readout following its acquisition of Forte Biosciences in August 2026. FB102 has FDA Fast Track designation for celiac disease and remains under evaluation for vitiligo and alopecia areata.

argenx shares fell after it stopped a Phase 3 Sjögren’s trial for futility, even as FB102 met its Phase 2 goal in celiac disease.

YouTube video by New Order - Topic

Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) and argenx SE (NASDAQ:ARGX) announced positive topline results on August 17 from their Phase 3